Table 1

Summary of baseline characteristics and deferral strategies from randomized controlled trials comparing deferred vs immediate initiation of antiretroviral therapy (ART) in ART-naïve HIV+ persons
Study (reference) Sample size Median baseline CD4 count (cells/μl) Deferral strategy Median CD4 count (cells/μl) at ART initiation in the deferred arm
SMART [29] 249 437 ART deferred until: 245
1. CD4 declined to <250 cells/μl
2. CD4 percentage declined to <15%
3. Symptoms of HIV disease developed
CIPRA HT-001 [30] 816 281 ART deferred until: 166
1. CD4 declined to ≤200 cells/μl
2. AIDS-defining illness developed
HPTN 052 [9] 1,761 428 ART deferred until: 299
1. CD4 declined to ≤250 cells/μl
2. AIDS-defining illness developed

Lundgren et al.

Lundgren et al. BMC Medicine 2013 11:148   doi:10.1186/1741-7015-11-148

Open Data